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In 2018, cemiplimab-rwlc became the first systemic treatment approved by the US FDA for patients with
metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for
curative surgery or curative radiation. In 2019, conditional approvals were granted by Health Canada and
the European Commission for the same indications. Limited data exist pertaining to the clinical characteristics, disease progression and survivorship of patients with advanced CSCC in real-world clinical practice.
CemiplimAb-rwlc Survivorship and Epidemiology (CASE) is a prospective Phase IV, noninterventional, survivorship and epidemiology study that will enroll patients with advanced CSCC who have recently initiated
or who plan to receive cemiplimab in a real-world setting. Trial registration number: NCT03836105.
Lay abstract: Cutaneous squamous cell carcinoma (CSCC) is a common form of skin cancer that is usually
cured by surgery. When it progresses to a form that is incurable by surgery and/or radiotherapy, it is
classified as advanced CSCC. Cemiplimab is a therapy that unleashes the immune system to fight cancer. It
is the only treatment approved in the USA, Canada and Europe for the treatment of advanced CSCC. Little
information exists on cemiplimab clinical experience outside of clinical trials. CASE is a Phase IV study that
will collect outcomes data from patients with advanced CSCC receiving cemiplimab in a real-world setting.
First draft submitted: 20 November 2019; Accepted for publication: 17 December 2019; Published
online: 17 January 2020
Keywords: advanced CSCC • cemiplimab • CSCC • cutaneous squamous cell carcinoma • epidemiology • PD-1
inhibitor • real-world data • survivorship

Cutaneous squamous cell carcinoma (CSCC) is one of the most common cancers worldwide and is rivaled in
incidence only by basal cell carcinoma as the most common cancer in the USA [1,2]. In most cases, early stage
CSCC can be cured by surgery [3]. However, a small percentage of patients develop advanced CSCC, a term that
comprises metastatic CSCC and locally advanced CSCC no longer amenable to curative surgery and/or curative
radiation. Radiotherapy alone or in combination with chemotherapy is an option for some patients with locally
advanced CSCC who are not amenable to surgery. However, radiotherapy alone is associated with a recurrence rate
of 30% for these patients [4,5].
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Advanced CSCC is associated with high mortality rate and poor prognosis [6,7]. Until recently, there was no
approved systemic therapy for patients with advanced CSCC, and systemic treatment options were often adopted
from head and neck squamous cell carcinoma treatment regimens. Limited evidence shows that patients with
advanced CSCC may respond to cytotoxic chemotherapy or targeted therapy such as EGFR inhibitors. However,
efficacy of these treatments is moderate, the responses are rarely durable and the treatments are associated with
significant toxicity [6,8,9].
Cemiplimab is a high-affinity, human, hinge-stabilized IgG4 monoclonal antibody to the PD-1 receptor that
potently blocks the interactions of PD-1 with PD-ligand 1 and PD-ligand 2 [10]. Cemiplimab demonstrated
substantial antitumor activity with durable responses in patients with metastatic or locally advanced CSCC in
Phase I expansion cohorts and a Phase II study [11–13].
In the USA, cemiplimab-rwlc is the only FDA-approved treatment for patients with metastatic CSCC or
locally advanced CSCC who are not candidates for curative surgery or curative radiation [14]. The National
Comprehensive Cancer Network (NCCN) has included the aforementioned indications in their guidelines as a
systemic therapy option [5]. In April 2019 and July 2019, Health Canada and the European Commission (EC),
respectively, granted conditional approvals for, and the Brazilian Health Authority recommended the use of,
cemiplimab for the aforementioned indications [15–17]. The UK National Institute for Health and Care Excellence
has also recommended the use of cemiplimab, within the Cancer Drugs Fund, as an option for the treatment of
the aforementioned indications [18].
Background & rationale
Given that CSCC data are not collected in most national cancer registries, there are limited data on the presenting
clinical characteristics, therapeutic sequence, disease course, patient-reported outcomes and survivorship of patients
with advanced CSCC in the real-world clinical setting. Recent approval of cemiplimab for this patient population
presents an opportunity to identify disease characteristics of patients with advanced CSCC in real-world practice,
and prospectively describe this patient group and evolution of their disease.
In routine clinical practice settings, patients will likely receive cemiplimab at various timepoints (e.g., first-line,
second-line) in their respective treatment pathway of advanced CSCC. Some patients receiving treatment are also
expected to have clinically relevant comorbid conditions (e.g., immunosuppression due to transplant/autoimmune
disease or hematologic cancers such as chronic lymphocytic leukemia) that are commonplace in real life, even
though patients with these conditions were excluded from registrational trials. Data from real-world experience
with cemiplimab in advanced CSCC will assist in identifying treatment patterns, survivorship and epidemiologic
aspects of the disease that have not yet been studied.
CASE study

CASE (CemiplimAb-rwlc Survivorship and Epidemiology; NCT03836105) is a Phase IV, multicenter, prospective,
noninterventional, survivorship and epidemiology cohort study of patients with advanced CSCC receiving cemiplimab in the real-world. CASE is the first survivorship and epidemiology study of patients with advanced CSCC
and is planned to represent the largest cohort of such patients receiving cemiplimab in a real-world setting. Here, we
describe the design and rationale for CASE, which will collect long-term data on characteristics and survivorship of
patients with advanced CSCC being treated with cemiplimab in clinical practice as their standard-of-care treatment,
and fill evidence gaps in the management of advanced CSCC.
Objectives

The objectives of this study are to describe the effectiveness of cemiplimab 350 mg administered every 3 weeks
intravenously in eligible patients, including in those who are immunosuppressed or immunocompetent, after
prior exposure to radiotherapy, and as a first-line or later systemic treatment; to evaluate the safety of cemiplimab
(based on the incidence of grade ≥3 immune-related adverse events, grade ≥2 infusion-related reactions and
treatment-related serious adverse events) in eligible patients; to describe patient and clinical characteristics and
potential associations with outcomes; to describe the use patterns of cemiplimab for the treatment of advanced
CSCC; and to describe patient experience, including patient-reported quality of life (QoL), functional status and
clinician-reported performance status in a real-world setting for patients with advanced CSCC.
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Table 1. Inclusion & exclusion criteria.
Inclusion criteria

Exclusion criteria

• Patients aged 18 years or older were eligible for treatment with cemiplimab for
advanced CSCC in accordance with approved prescribing information:
- Patients who are continuing treatment with cemiplimab after completing
cemiplimab treatment on the Phase II clinical trial of cemiplimab in
advanced CSCC are eligible to participate in this study at the time that they
initiate treatment with cemiplimab in a real-world setting;
- It is recommended that patients are enrolled prior to administration of their
third dose of cemiplimab.
• Willingness and ability to comply with standard clinical care for advanced CSCC;
• Ability to understand and complete study-related questionnaires;
• Provision of signed informed consent.

• Treatment with cemiplimab for an indication other than advanced CSCC;
• Any condition that, in the opinion of the investigator, may interfere with patient’s
ability to participate in the study (e.g., unstable social situation such as
homelessness, or psychiatric conditions such as schizophrenia, advanced depression,
active substance abuse or severe cognitive impairment or other comorbidities) or
other comorbidities that would, in the opinion of the investigator, predictably limit
compliance with the intended treatment plan, or prevent adequate completion of
QoL assessments;
• Concurrent participation in any study including those that involve administration
of investigational therapy (including cemiplimab) or procedure (including survival
follow-up).

CSCC: Cutaneous squamous cell carcinoma; QoL: Quality of life.

Table 2. Estimated precision (95% confidence interval) for various outcome event rates by sample size after dropout.
End point

%

95% CI by sample size
n = 250

n = 300

n = 350

n = 400

Objective response rate

45

38.8–51.2

39.4–50.6

39.8–50.2

40.1–49.9

Disease control rate

65

59.1–70.9

59.6–70.4

60.0–70.0

60.3–69.7

Overall survival at
12 months

80

75.0–85.0

75.5–84.5

75.8–84.2

76.1–83.9

Overall survival at 2 years

55

48.8–61.2

49.4–60.6

49.8–60.2

50.1–59.9

Grade ≥3 irAEs†

8

4.6–11.4

4.9–11.1

5.2–10.8

5.3–10.7

Grade ≥2 infusion-related
reaction‡

3.7

1.4–6.0

1.6–5.8

1.7–5.7

1.9–5.5

† Per

the European Union risk management plan at day 180.
Phase II study of cemiplimab in advanced CSCC (data cut-off of 27 October 2017) and Phase I study of cemiplimab in advanced CSCC (data cut-off was 2 October 2017 for patients
with advanced CSCC who received cemiplimab monotherapy, and data cut-off was 1 September 2017 for all other patients).
CI: Confidence interval; irAE: Immune-related adverse event.

‡ Per

Design
Study design
CASE is a prospective, noninterventional, noncomparative longitudinal survivorship cohort study of adult patients
with advanced CSCC receiving cemiplimab in the real-world setting. The type and frequency of patient visits and
all evaluations will be performed as done in real-world clinical practice. Patients will be enrolled at up to 100 study
sites in the USA. Study sites in other countries may be initiated after the approval and availability of cemiplimab
in those countries. Implementation of the study protocol and all amendments require approval by the institutional
review board and the ethics committee at each participating study site. The study is being conducted in accordance
with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good
Clinical Practice guidelines. Informed consents will be provided by patients before enrollment.
Eligibility criteria

Patients in this study will include men and women ≥18 years of age who have recently initiated, or are about to
initiate, treatment with commercially available cemiplimab for advanced CSCC. Patients who meet all eligibility
criteria (Table 1) will be included in the study. Patients who do not initiate cemiplimab within 4 weeks of signing
informed consent may not participate unless they undergo additional screening and consent procedures; the reason
for not initiating cemiplimab will be documented. These patients will be eligible to participate in the study with no
waiting period should they subsequently provide informed consent and decide to start treatment with cemiplimab
at a later date.
Planned sample size & study period

CASE will target enrollment of 350 patients with advanced CSCC in the USA based on the assumptions summarized
in Tables 2 and 3. The planned duration of enrollment is approximately 24 months (Figure 1). If the target of 350
patients is reached prior to the 24-month enrollment period, no more than 500 patients will be enrolled. Each
patient will be followed up for up to 36 months.
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Table 3. Estimated precision (95% confidence intervals) of event rates per observed incidences of adverse events of
special interest from cemiplimab clinical trials by sample size after dropout.
Sample size (n)

Observed event incidence (%)
0.5

0.7

1.0

5.0

7.0

350

0.0–1.2

0.0–1.6

0.0–2.0

2.7–7.3

4.3–9.7

300

0.0–1.3

0.0–1.6

0.0–2.1

2.5–7.5

4.1–9.9

250

0.0–1.4

0.0–1.7

0.0–2.2

2.3–7.7

3.8–10.2

Year
Quarter

2019
2017
2018
2023
2021
2022
2020
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

Up to 350 patients
to be enrolled
in the US
Patients with advanced
CSCC initiating treatment
with cemiplimab
post regulatory approval

Cemiplimab
US FDA submission
E
N
R
O
L
L

Follow-up per
routine clinical
practice, at
least every
3 months

Cemiplimab
US FDA approval
Follow-up
for 3 years

Off-study
at 3 years

Enroll
Follow-up
Data extract
Data publication

Figure 1. Study design. The target of 350 patients is for the US study only.
CSCC: Cutaneous squamous cell carcinoma.

Study procedure

No investigational agents will be provided by the study sponsor to the patients enrolled in CASE. At each
participating site, eligible patients will be screened and offered the opportunity to participate in the study until the
enrollment goal is achieved. The decision to prescribe cemiplimab will be based solely on the clinical judgment of
the treating physician per the participating investigator’s standard of care. Upon provision of informed consent and
enrollment in the study, patients will be followed up by their treating physician per routine clinical practices with
the longest or maximum elapsed time between clinical visits to be 3 months. All visits will be documented in the
electronic case report forms.
After enrollment, patients will continue on study irrespective of cemiplimab treatment status (i.e., temporary
or permanent discontinuation) for continued collection of data, unless consent is withdrawn by the patient. For
patients who decline further participation from the study (i.e., decline to have data captured or decline to participate
in patient-reported outcome documentation), information on survival will continue to be collected at 3-month
intervals, for the full 36-month follow-up period, unless the patient withdraws consent to be followed up for
survival. Patients may receive other therapies, in addition to cemiplimab, as deemed necessary by their physicians
for the treatment of advanced CSCC or comorbid conditions.
Outcome measures

Patient and tumor baseline characteristics will be collected prior to the start of cemiplimab treatment in the realworld clinical treatment settings. Outcome measures of CASE include effectiveness of treatment, safety, treatment
patterns and patient experience. Further details on each outcome measure are provided in Box 1.
Statistical assumptions & analysis

Data will be requested for transcription to electronic case report forms. Records of laboratory tests, clinical
notes, patient medical records, patient questionnaires and correspondence with other healthcare professionals (if
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Box 1. Study outcomes of interest
Patient and tumor characteristics
• Demographics;
• Comorbidity diagnoses and medication history;
• CSCC medical/surgical/radiation history;
• ECOG performance status;
• Other primary cancer with medical/surgical history;
• Baseline physical exam;
• HRQoL.
Treatment effectiveness
• Objective response rate per investigator assessment;
• Disease control rate per investigator assessment;
• Duration of responsel;
• Time to response;
• Progression-free survival;
• Overall survival;
• Time to treatment failure, including lack of response and discontinuation due to adverse events;
• Disease-specific death rate;
• Pattern of response and pattern of recurrence;
Safety
• Treatment-related irAEs and IRRs per physician assessments. Data will be coded and categorized using MedDRA
and graded per the National Cancer Institute Common Terminology Criteria for Adverse Events version 5;
• Treatment-related SAEs per physician assessments, coded and categorized using MedDRA.
Treatment patterns & related outcomes
• Interventions for advanced CSCC treatment (e.g., surgery, radiation, drug therapy) prior to the initiation of
cemiplimab treatment, if applicable;
• Pattern of response and pattern of recurrence;
• Concomitant medications;
• Treatment of irAEs (e.g., systemic corticosteroids, noncorticosteroid treatment and hormone-replacement
therapies);
• Determinants of disease sequelae (recurrence, metastasis);
• Longitudinal effectiveness of advanced CSCC interventions;
• Duration of treatment prior to cemiplimab;
• Health services utilization;
• Reason for discontinuation of cemiplimab (e.g., lack of effectiveness, adverse events, complete response or
prolonged partial response);
• Interventions for advanced CSCC treatment (e.g., surgery, radiation, drug therapy) following initiation of
cemiplimab treatment, including dates of administration, premedications administered (if any), dosage and
administration details, reasons for and dates of dose delays and reason for and dates of treatment
discontinuation.
Patient experience
• HRQoL and disease-related symptoms will be captured at baseline and follow-up visits using the following tools:
◦ EORTC QLQ-C30: to assess HRQoL across five functional scales (physical, role, emotional, cognitive, social), a
global health status/QoL scale, three symptom scales (fatigue, nausea and vomiting and pain), and six
individual symptoms (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties);
◦ EORTC QLQ-ELD14: five scales (mobility, worries about others, worries about future, maintaining purpose,
burden of illness), two single items (joint stiffness and family support);
◦ SCI: three scales (emotional, social, appearance);
◦ Pain NRS: to assess pain intensity;
◦ SEBI: to assess exposure to sun.
CSCC: Cutaneous squamous cell carcinoma; ECOG: Eastern Cooperative Oncology Group; EORTC QLQ: European Organisation for
Research and Treatment of Cancer Quality of Life Questionnaire; HRQoL: Health-related QoL; irAE: Immune-related adverse event;
IRR: Infusion-related reaction; MedDRA: Medical Dictionary for Regulatory Activity; NRS: numeric rating scale; QoL: Quality of life;
SAE: Serious adverse event; SCI: Skin cancer index; SEBI: Sun exposure and behavior inventory; .

applicable) in the patient files will be the original source documents. There is no formal statistical hypothesis to
test nor a planned inferential comparison. Data will be summarized descriptively (for continuous variables), by
frequencies and percentages (for categorical and ordinal data) or by Kaplan–Meier estimation and duration-adjusted
statistics (for time to event).
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Discussion
There is limited information on overall disease burden, health status, QoL and survivorship of patients with advanced
CSCC and those receiving cemiplimab in the real-world clinical setting. While clinical trials are important for
evaluating medical benefits of treatments for various cancers, real-world data are becoming increasingly important
in healthcare decision making as they provide evidence on long-term treatment effectiveness and safety in clinical
practice in a patient cohort more reflective of day-to-day clinical practice [19,20]. Currently available real-world
evidence for advanced CSCC are mainly based on retrospective analyses [6,21]. A real-world study with prospective
evaluation of patients, long study period and long patient follow-up, such as in CASE, provides an opportunity for
collection of robust data on patients with advanced CSCC.
The Phase II study of cemiplimab in advanced CSCC was the largest prospective clinical trial of patients with
advanced CSCC receiving systemic therapy [11]. However, there is still a need to continue to expand available
clinical data on CSCC treatment outcomes including efficacy, safety, treatment patterns and QoL of patients
treated with cemiplimab. Prior to September 2018, there was no approved systemic therapy for treating advanced
CSCC. Furthermore, due to limited available evidence, there is lack of consensus on treatment approach (surgery,
radiation, systemic therapy) for patients with this disease. Given that cemiplimab is the first systemic agent approved
for the treatment of patients with metastatic CSCC or locally advanced CSCC who are not candidates for curative
surgery or curative radiation [14], there is a need for a pragmatic study to better understand the disease and clinical
benefit of the approved treatment outside of a clinical setting.
The drivers of this undertaking are relevant to clinical practice and outcomes-based investigation. While clinical
trials often include eligibility criteria that aim to ensure homogenous and representative patient populations, these
criteria may exclude patients with certain disease characteristics and/or comorbidities such that available evidence
from the clinical trial can only be extrapolated to patients with a similarly narrow clinical makeup. As an example,
in the Phase II study of cemiplimab in advanced CSCC, patients who had undergone solid organ transplantation or
those who were immunosuppressed were excluded [11]. As such, the clinical benefit of cemiplimab in those groups
of patients is unknown. In the real-world setting, treatment decisions are dependent on multiple patient factors.
Strict eligibility criteria such as those imposed in a clinical study will most likely not apply in real-world clinical
practice. Hence, CASE may be able to help bridge the evidence gap and provide clinicians with real-world data on
the potential clinical benefit of cemiplimab in patient groups not included in the clinical trials.
Given the rapidly evolving treatment landscape but limited supporting evidence for broad, population-based
cancer care, a multidisciplinary working group (consisting of the American College of Surgeons Commission on
Cancer, the American Society for Radiation Oncology, the American Society of Clinical Oncology, the Society of
Interventional Radiology, and the Society of Surgical Oncology) recently provided consensus recommendations
on approaches to fill knowledge gaps where a controlled randomized clinical trial is absent, not achievable or
not necessary in cancer research [22]. The recommendations include promotion of cross-disciplinary research,
conduction of more pragmatic studies, use of health information technology to facilitate observational research and
use of reimbursement strategies to incentivize evidence development [22].
CASE is a prospective analysis of outcomes and long-term effectiveness of cemiplimab in patients with advanced
CSCC, and moreover promotes cross-disciplinary research between treating dermatologists, surgeons, radiation
oncologists and medical oncologists. Furthermore, CASE will not only collect real-world evidence relating to cemiplimab, but also collect and analyze additional information such as the medical history, prior treatments, outcomes
and progression patterns of patients participating in the study. Finally, CASE will also collect patient-reported
outcomes, a patient perspective that provides a value-based assessment of treatment [23], and thus supplement
evidence generated during clinical trials.
CASE is currently only opened for enrollment in the USA; additional study sites outside of the USA may
be opened upon approval in those countries. Furthermore, as CASE is a survivorship study of cemiplimab in
the real-world setting, the study may be extended to additional tumor types based upon approval within those
indications.
Conclusion
Until recently, there was no approved systemic therapy for patients with advanced CSCC. Currently, cemiplimabrwlc is the only systemic treatment approved by the US FDA for the treatment of patients with advanced
CSCC [14]. It has also received conditional approval in the European Union and Canada, and a recommendation
by the Brazilian Health Authority, for the aforementioned indications [15–17]. The UK National Institute for Health
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and Care Excellence has also recommended the use of cemiplimab (within the Cancer Drugs Fund) for the same
indications [18], and additional reimbursement approvals/recommendations in other countries are expected over
time. With the emerging need for insight on the clinical characteristics, disease course and survivorship of patients
with advanced CSCC receiving cemiplimab in the real-world clinical setting, CASE will provide an opportunity
to collect long-term data on the use of cemiplimab in clinical practice and fill evidence gaps in the management of
patients with advanced CSCC in the real world.

Executive summary
Advanced cutaneous squamous cell carcinoma
• A small percentage of patients with cutaneous squamous cell carcinoma (CSCC) develop advanced CSCC, a term
that comprises metastatic CSCC and locally advanced CSCC not amenable to curative surgery and/or radiotherapy.
• Cemiplimab-rwlc is the only US FDA approved treatment for patients with metastatic CSCC or locally advanced
CSCC who are not candidates for curative surgery or curative radiation.
• The NCCN guidelines have included the aforementioned indications in their guidelines as a systemic therapy
option.
• Health Canada and the EC granted conditional approvals of, and the Brazilian Health Authority and the UK
National Institute for Health and Care Excellence recommended cemiplimab for the aforementioned indications.
CASE study
• There is limited information on the presenting clinical characteristics, therapeutic sequence, disease course,
patient-reported outcomes and survivorship of patients with advanced CSCC in real-world clinical practice.
• CASE is a prospective survivorship and epidemiology cohort study of patients with advanced CSCC receiving
cemiplimab in the real-world setting.
• CASE will collect long-term data from patients with advanced CSCC being treated with cemiplimab in clinical
practice and fill evidence gaps in the management of advanced CSCC.
Objectives
• To describe the effectiveness of cemiplimab 350 mg administered every 3 weeks intravenously in eligible patients,
and:
◦ In immunosuppressed and immunocompetent patients;
◦ After prior exposure to radiotherapy;
◦ As a first-line or later systemic treatment.
• To evaluate the safety of cemiplimab (based on the incidence of Grade ≥3 immune-related adverse events, Grade
≥2 infusion-related reactions and treatment-related serious adverse events) in eligible patients.
• To describe patient and clinical characteristics and potential associations with outcomes.
• To describe the real-world use patterns of cemiplimab for the treatment of advanced CSCC.
• To describe patient experience, including patient-reported QoL and functional status and clinician-reported
performance status in a real-world setting.
Study design & eligibility
• Patients will include men and women ≥18 years of age who have recently initiated or who plan to initiate
treatment with commercially available cemiplimab for the treatment of advanced CSCC in real-world clinical
settings.
• The type and frequency of patient visits and all evaluations will be performed as done in real-world clinical
practice.
• Approximately 350 patients will be enrolled at up to 100 study sites in the USA.
• No investigational agents will be provided by the study sponsor; the decision to prescribe cemiplimab will be
based solely on the clinical judgment of the treating physician per the local standard of care.
Outcome measures of interest
• Patient and tumor characteristics.
• Treatment effectiveness.
• Safety.
• Treatment patterns and related outcomes.
• Patient experience.
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